ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Syndax Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 0.83%
- The company has been able to generate a Return on Equity (avg) of 0.83% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 11 consecutive quarters
- INTEREST(HY) At USD 15.91 MM has Grown at 15,809%
- OPERATING CASH FLOW(Y) Lowest at USD -302.67 MM
- ROCE(HY) Lowest at -113.22%
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 16.26%, its profits have fallen by -37.6%
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.84% over the previous quarter and currently hold 6.6% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Syndax Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Syndax Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Syndax Pharmaceuticals, Inc.
18.77%
-0.02
70.16%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
119.91%
EBIT Growth (5y)
-230.17%
EBIT to Interest (avg)
-75.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.83%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.58
EV to EBIT
-2.38
EV to EBITDA
-2.38
EV to Capital Employed
17.37
EV to Sales
18.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-730.60%
ROE (Latest)
-154.01%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
NET PROFIT(HY)
Higher at USD -156.69 MM
RAW MATERIAL COST(Y)
Fallen by -9,663% (YoY
CASH AND EQV(HY)
Highest at USD 967.43 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 0.34 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.24 times
NET SALES(Q)
Highest at USD 37.96 MM
OPERATING PROFIT(Q)
Highest at USD -69.35 MM
OPERATING PROFIT MARGIN(Q)
Highest at -182.71 %
-14What is not working for the Company
INTEREST(HY)
At USD 15.91 MM has Grown at 15,809%
OPERATING CASH FLOW(Y)
Lowest at USD -302.67 MM
ROCE(HY)
Lowest at -113.22%
DEBT-EQUITY RATIO
(HY)
Highest at -69.69 %
Here's what is working for Syndax Pharmaceuticals, Inc.
Net Sales
At USD 37.96 MM has Grown at 984.51%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Profit
Higher at USD -156.69 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Sales
Highest at USD 37.96 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -69.35 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -182.71 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Cash and Eqv
Highest at USD 967.43 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 0.34 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.24 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -9,663% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Syndax Pharmaceuticals, Inc.
Interest
At USD 15.91 MM has Grown at 15,809%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -302.67 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -69.69 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
